K Number
K122434
Device Name
MEROGEL INJECTABLE BIORESORBABLE NASAL DRESSING AND SINUS STENT AND OTOLOGIC GEL
Manufacturer
Date Cleared
2012-10-31

(82 days)

Product Code
Regulation Number
874.3620
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is a space occupying gel stent intended to separate and prevent adhesions between mucosal surfaces, help control minimal bleeding following surgery or nasal trauma, and act as an adjunct to aid in the natural healing process. MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is indicated for use in the middle ear and external ear canal following canalplasty, myringoplasty, tympanoplasty, and stapes and mastoid surgery. The device is indicated following nasal / sinus surgery or trauma to prevent lateralization of the middle turbinate and nasal adhesions during the post operative period.
Device Description
MeroGel is a sterile, transparent, viscoelactic, bioresorbable gel composed of cross-linked polymers of hyaluronic acid. The MeroGel device fills ENT cavities following surgery or trauma to keep tissues or structures separate during the healing process. During this time, the tamponade effect helps control minimal bleeding normally associated with routine ENT surgery. MeroGel leaves the site of placement by natural elimination, or it may be aspirated from the cavity earlier at the discretion of the physician.
More Information

No
The device description and performance studies focus on the physical properties and function of a bioresorbable gel, with no mention of AI or ML capabilities.

Yes.
The device is intended to separate tissues, control bleeding, and act as an adjunct to aid in the natural healing process, all of which are therapeutic functions.

No

The device is described as a "space occupying gel stent intended to separate and prevent adhesions," "help control minimal bleeding," and "act as an adjunct to aid in the natural healing process." It functions therapeutically or as a physical barrier, not to identify or characterize a disease or condition.

No

The device description clearly states it is a "sterile, transparent, viscoelactic, bioresorbable gel composed of cross-linked polymers of hyaluronic acid," which is a physical substance, not software.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use describes a device that is physically placed within the body (middle ear, external ear canal, nasal/sinus cavities) to provide structural support, prevent adhesions, control bleeding, and aid healing. This is a therapeutic and supportive function, not a diagnostic one.
  • Device Description: The description details a physical gel composed of hyaluronic acid that fills cavities and separates tissues. This is consistent with a medical device used for physical intervention, not for analyzing samples from the body to diagnose a condition.
  • Lack of Diagnostic Elements: There is no mention of the device being used to analyze biological samples (blood, urine, tissue, etc.) or to provide information about a patient's health status based on such analysis.
  • Anatomical Site: The anatomical sites are internal body cavities, where the device is physically placed. IVDs typically interact with samples taken from the body.

In summary, the MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is a medical device used for physical support and healing within the body, not for performing in vitro diagnostic tests.

N/A

Intended Use / Indications for Use

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is a space occupying gel stent intended to separate and prevent adhesions between mucosal surfaces, help control minimal bleeding following surgery or nasal trauma, and act as an adjunct to aid in the natural healing process.

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is indicated for use in the middle ear and external ear canal following canalplasty, myringoplasty, tympanoplasty, and stapes and mastoid surgery. The device is indicated following nasal / sinus surgery or trauma to prevent lateralization of the middle turbinate and nasal adhesions during the post operative period.

Product codes

NHB

Device Description

MeroGel is a sterile, transparent, viscoelactic, bioresorbable gel composed of cross-linked polymers of hyaluronic acid. The MeroGel device fills ENT cavities following surgery or trauma to keep tissues or structures separate during the healing process. During this time, the tamponade effect helps control minimal bleeding normally associated with routine ENT surgery. MeroGel leaves the site of placement by natural elimination, or it may be aspirated from the cavity earlier at the discretion of the physician.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

middle ear, external ear canal, nasal / sinus

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The following tests were conducted in order to demonstrate that the MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is substantially equivalent to the MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel of K070886.

  • Formulation for viscosity and HA concentration .
  • . Filling process
  • Terminal Sterilization processes (primary and secondary) .
  • Assembly .
  • Biocompatibility .
  • Labeling and Packaging .

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K070886

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 874.3620 Ear, nose, and throat synthetic polymer material.

(a)
Identification. Ear, nose, and throat synthetic polymer material is a device material that is intended to be implanted for use as a space-occupying substance in the reconstructive surgery of the head and neck. The device is used, for example, in augmentation rhinoplasty and in tissue defect closures in the esophagus. The device is shaped and formed by the suregon to conform to the patient's needs. This generic type of device is made of material such as polyamide mesh or foil and porous polyethylene.(b)
Classification. Class II.

0

K1a2434

OCT 31 2012

510(k) SUMMARY SUMMARY OF SAFETY AND EFFECTIVENESS FOR

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel

| 510(k) Owner | Medtronic Xomed, Inc
6743 Southpoint Drive North
Jacksonville, Florida 32216-0980 USA
904-296-9600
904-296-2386 (FAX) |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Contact Name | Antoine Kouchakjy
Principal Regulatory Affairs Specialist
Medtronic Xomed, Inc |
| Date Summary Prepared | August 9, 2012 |
| Proprietary Name | MeroGel Injectable Bioresorbable Nasal Dressing and Sinus
Stent and Otologic Gel |
| Common Name | Polymer, Ear, Nose and Throat, Synthetic, Absorbable |
| Classification Name | Ear, nose and throat synthetic polymer material
(21 CFR 874.3620, Product Code NHB, Class II) |

Marketed device claiming equivalence to

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel (MeroGel) is equivalent to Medtronic Xomed's MeroGel Injectable Bioresorbable Stent, K070886.

Device Description

MeroGel is a sterile, transparent, viscoelactic, bioresorbable gel composed of cross-linked polymers of hyaluronic acid. The MeroGel device fills ENT cavities following surgery or trauma to keep tissues or structures separate during the healing process. During this time, the tamponade effect helps control minimal bleeding normally associated with routine ENT surgery. MeroGel leaves the site of placement by natural elimination, or it may be aspirated from the cavity earlier at the discretion of the physician.

Intended Use

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is a space occupying gel stent intended to separate and prevent adhesions between mucosal surfaces, help control minimal bleeding following surgery or nasal trauma, and act as an adjunct to aid in the natural healing process.

Indications for Use

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is indicated for use in the middle ear and external ear canal following canalplasty, myringoplasty, tympanoplasty, and stapes and mastoid surgery. The device is indicated following nasal / sinus surgery or trauma to prevent lateralization of the middle turbinate and nasal adhesions during the post operative period.

1

Summary of Changes

  • Manufacturing site change. .
  • . Secondary sterilization method change
  • Sterilization pouch material change. .

Summary of Testing

The following tests were conducted in order to demonstrate that the MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is substantially equivalent to the MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel of K070886.

  • Formulation for viscosity and HA concentration .
  • . Filling process
  • Terminal Sterilization processes (primary and secondary) .
  • Assembly .
  • Biocompatibility .
  • Labeling and Packaging .

2

| Device Name | MeroGel Injectable Bioresorbable Nasal
Dressing and Sinus Stent and Otologic Gel
Medtronic Xomed
510(k) PROPOSED | MeroGel Injectable Bioresorbable Stent
Medtronic Xomed
K070886 |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Product Code | ENT synthetic polymer material | ENT synthetic polymer material |
| Intended Use / Indication | NHB
Same as K070886:
MeroGel Injectable Bioresorbable Nasal
Dressing and Sinus Stent and Otologic Gel
is a space occupying gel stent intended to
separate and prevent adhesions between
mucosal surfaces, help control minimal
bleeding following surgery or nasal
trauma, and act as an adjunct to aid in the
natural healing process.
MeroGel Injectable Bioresorbable Nasal
Dressing and Sinus Stent and Otologic Gel
is indicated for use in the middle ear and
external ear canal following canalplasty,
myringoplasty, tympanoplasty, and stapes
and mastoid surgery. The device is
indicated following nasal / sinus surgery or
trauma to prevent lateralization of the
middle turbinate and nasal adhesions
during the post operative period. | NHB
MeroGel Injectable Bioresorbable Stent is
a space occupying gel stent intended to
separate and prevent adhesions between
mucosal surfaces, help control minimal
bleeding following surgery or nasal
trauma, and act as an adjunct to aid in the
natural healing process.
MeroGel Injectable Bioresorbable Stent is
indicated for use in the middle ear and
external ear canal following canalplasty,
myringoplasty, tympanoplasty, and stapes
and mastoid surgery. The device is
indicated following nasal / sinus surgery or
trauma to prevent lateralization of the
middle turbinate and nasal adhesions
during the post operative period. |
| Material | Derivative hyaluronic acid | Derivative hyaluronic acid |
| Bioresorbable | YES | YES |
| Sterile | YES | YES |
| Product Matrix | Gel in a syringe | Gel in a syringe |

.

.

Section 08 - 510(k) Summary : MeroGel Injectable

3

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, facing to the right. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002

OCT 31 2012

Medtronic Xomed, Inc. % Mr. Antoine Kouchakjy Principal Regulatory Affairs Specialist 6743 Southpoint Drive North Jacksonville, FL 32216-0980

Re: K122434

Trade/Device Name: MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel

Regulation Number: 21 CFR 874.3620

Regulation Name: Ear, nose, and throat synthetic polymer material

Regulatory Class: Class II

Product Code: NHB

Dated: September 28, 2012

Received: October 1, 2012

Dear Mr. Kouchakjy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

4

forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Makin D. Ficklen, M.D.

Malvina B. Eydelman, M Director Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

5

Indications for Use

510(k) Number (if known):

KI22434

Device Name:

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel

Indications For Use:

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is a space occupying gel stent intended to separate and prevent adhesions between mucosal surfaces, help control minimal bleeding following surgery or nasal trauma, and act as an adjunct to aid in the natural healing process.

MeroGel Injectable Bioresorbable Nasal Dressing and Sinus Stent and Otologic Gel is indicated for use in the middle ear and external ear canal following canalplasty, myringoplasty, and stapes and mastoid surgery. The device is indicated following nasal / sinus surgery or trauma to prevent lateralization of the middle turbinate and nasal adhesions during the post operative period.

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

Page 1 of

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Daniel C. Clupper

Division Sign-Off) · >>vision of Ophthalmic, Neurological and Ear, ivose and Throat Devices

K122434
510(k) Number